Across TCGA pan-cancer cohorts, IGLC2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated IGLC2 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher IGLC2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGLC2 expression acts as an unfavorable survival marker.

SKCM are the cancer types where IGLC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	All	0.067	0.739	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: IGLC2 tumor-vs-normal RNA expression · all IGLC2 data types